當前位置:首頁 >> 資料下載 >> Targeting HSP90 dimerization via theC terminus is effective in imatinib-resistant
提供商
上海協爍儀器科技有限公司資料大小
2.3MB資料圖片
下載次數
0次資料類型
PDF 文件瀏覽次數
226次Heat shock protein 90 (HSP90) stabilizes many client proteins, including the BCR-ABL1
oncoprotein. BCR-ABL1 is the hallmark of chronic myeloid leukemia (CML) in which
treatment-free remission (TFR) is limited, with clinical and economic consequences. Thus,
there is an urgent need for novel therapeutics that synergize with current treatment
approaches. Several inhibitors targeting the N-terminal domain of HSP90 are under investigation, but side effects such as induction of the heat shock response (HSR) and toxicity
have so far precluded their US Food and Drug Administration approval. We have developed a novel inhibitor (aminoxyrone [AX]) of HSP90 function by targeting HSP90 dimerization via the C-terminal domain.
請輸入賬號
請輸入密碼
請輸驗證碼
以上信息由企業自行提供,信息內容的真實性、準確性和合法性由相關企業負責,化工儀器網對此不承擔任何保證責任。
溫馨提示:為規避購買風險,建議您在購買產品前務必確認供應商資質及產品質量。